Treatment of Minimal Residual Diseasein Myeloid Leukemia—The Immunotherapeutic Options with Emphasis on Linomide

References

• Rowe J. M., Cassileth P. A., Oken M. M., Anderson J. W., Bennett J. M., Wiernik P. H. Clinical trials in adults with acute myelogenous leukemia: The ECOG experience. Acute Myelogenous Leukemia: Progress and Controversies, R. P. Gale. Wiley-Liss, New York 1990; 293–302
   Google Scholar
• Schiffer C. A., Mayer R. J. Cancer and leukemia Group B (CALGB) studies in acute myeloid leukemia. Acute Myelogenous Leukemia: Progress and Controversies, R. P. Gale. Wiley-Liss, New York 1990; 313–322
   Google Scholar
• Gutterman J. U., Hersh R. M., Rodriguez V., McCredie K. B., Mavligit G., Reed R., Burgess M. A., Smith T., Gehan E., Bodey G. P., Sr, Freireich E. J. Chemoimmunotherapy of adult acute leukaemia. Lancet 1974; 2: 1405–1409
   PubMed Web of Science ®Google Scholar
• Whiteside M. G., Cauchi M. N., Paton C., Stone J. Chemoimmunotherapy for maintenance in acute myeloblastic leukemia. Cancer 1976; 38: 1581–1586
   PubMed Web of Science ®Google Scholar
• Whittaker J. A. Immunotherapy in the treatment of acute leukaemia. Br. J. Haematol. 1980; 45: 187–193
   PubMed Web of Science ®Google Scholar
• Galton D. A. G., Kay H. E., Reizenstein P., Penchansky M., Vogler W. R., Whittaker J. A. Infection and second-remission rates in patients having immunotherapy for acute myeloid leukemia. Lancet 1977; 2: 973
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Begg C. B. Eastern Cooperative Oncology Group study of the cytochemistry of adult acute myeloid leukemia by correlation of subtypes with response and survival. Cancer Res. 1981; 41: 4833–4837
   PubMed Web of Science ®Google Scholar
• Ifrah N., James J. M., Viguie J. P. M., Marie J. P., Zittoun R. Spontaneous remission in adult acute leukemia. Cancer 1985; 56: 1187–1190
   PubMed Web of Science ®Google Scholar
• Enck R. E. Spontaneous complete remission in acute promyelocytic leukemia. N. Y. S. J. Med. 1985; 88: 662–663
   Google Scholar
• Takaue Y., Culbert S. J., van Eys J., Dalton W. T., Jr, Cork A., Trujillo J. M. Spontaneous cure of end-stage nonlymphocytic leukemia complicated with chloroma (granulocytic sarcoma). Cancer 1986; 58: 1101–1105
   PubMed Web of Science ®Google Scholar
• Jehn U. W., Mempel M. A. Spontaneous remission of acute myeloid leukemia. Blut 1986; 52: 165–168
   PubMedGoogle Scholar
• Passe S., Mike V., Mertelsmann R., Gee T. S., Clark-son B. D. Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up. Cancer 1982; 50: 1462–1471
   PubMed Web of Science ®Google Scholar
• Fefer A. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia. J. Nat. Cancer Inst. 1986; 76: 1275–1279
   PubMed Web of Science ®Google Scholar
• Champlin R., Gale R. P. Bone marrow transplantation for acute leukemia: recent advances and comparison with alternative therapies. Sem. Hematol. 1987; 24: 55–67
   PubMed Web of Science ®Google Scholar
• Weiden P. L., Sullivan K. M., Flournoy N., Storb R., Thomas E. D. Antileukemic effect of chronic graftversus-host disease: contribution to improved survival after allogeneic marrow transplantation. N. Eng. J. Med. 1981; 304: 1529–1533
   PubMed Web of Science ®Google Scholar
• Sullivan K. M., Fefer A., Witherspoon R. Graftversus-leukemia in man: Relationship with acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. Cellular Immunotherapy of Canter, R. L. Truitt, R. P. Gale, M. M. Bortin. Alan R. Liss, Inc., New York 1987; 391–399
   Google Scholar
• Gale R. P., Champlin R. E. How does bone-marrow transplantation cure leukaemia?. Lancet 1984; 2: 28–30
   PubMed Web of Science ®Google Scholar
• Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H. J., Rimm A. A., Ringden O., Rozman C., Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Weisdorf D. J., Nesbit M. E., Ramsay N. K. C., Woods W. G., Goldman A. I., Kim T. H., Hurd D. D., McGlave P. B., Kersey J. H. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease. J. Clin. Oncol. 1987; 5: 1348–1355
   PubMed Web of Science ®Google Scholar
• Butturini A., Bortin M. M., Gale R. P. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant 1987; 2: 233–242
   PubMed Web of Science ®Google Scholar
• Fefer A., Sullivan K. M., Weiden P., Buckner C. D., Schoch G., Storb R., Thomas E. D. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog. Clin. Bio. Res. 1987; 244: 401–408
   PubMedGoogle Scholar
• Sullivan K. M., Storb R., Buckner C. D., Fefer A., Fisher L., Weiden P. L., Witherspoon R. P., Appelbaum F. R., Banaji M., Hansen J., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N. Eng. J. Med. 1989; 320: 828–834
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Gale R. P., Horowitz M. M., Biggs J. C., Champlin R. E., Gluckman E., Hoffmann R. G., Jacobsen S. J., Marmont A. M., McGlave P. B. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann. Int. Med. 1988; 108: 806–814
   PubMed Web of Science ®Google Scholar
• Butturini A., Gale R. P. The role of T-cells in preventing relapse in chronic myelogenous leukemia. Bone Marrow Transplant. 1987; 2: 351–354
   PubMed Web of Science ®Google Scholar
• Bearman S. I., Appelbaum F. R., Buckner C. D., Peter-sen F. B., Fisher L. D., Clift R. A., Thomas E. D. Regimen-related toxicity in patients undergoing bone marrow transplantation. J. Clin. Oncol. 1988; 6: 1562–1568
   PubMed Web of Science ®Google Scholar
• Kersey J. H., Weisdorf D., Nesbit M. E., LeBien T. W., Woods W. G., McGlave P. B., Kim T., Vallera D. A., Goldman A. I., Bostrom B., et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N. Engl. J. Med. 1987; 317: 461–467
   PubMed Web of Science ®Google Scholar
• Santos G. W., Tutschka P. J., Brookmeyer R., Saral R., Beschorner W. E., Bias W. B., Braine H. G., Burns W. H., Elfenbein G. J., Kaizer H., et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N. Eng. J. Med. 1983; 309: 1347–1353
   PubMed Web of Science ®Google Scholar
• Clift R. A., Buckner C. D., Thomas E. D., Kopecky K. J., Appelbaum F. R., Tallman M., Storb R., Sanders J., Sullivan K., Banaji M., et al. The treatment of acute non-Iymphoblastic leukemia by altogeneic marrow transplantation. Bone Marrow Transplant. 1987; 2: 243–258
   PubMed Web of Science ®Google Scholar
• Barrett A., Jiang Y. Z. Immune responses to chronic myeloid leukaemia. Bone Marrow Transplant. 1992; 9: 305–311
   PubMed Web of Science ®Google Scholar
• Sosman J. A., Oettel K. R., Smith S. D., Hank J. A., Fisch P., Sondel P. M. Specific recognition of human leukemic cells by allogeneic T-cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood 1990; 75: 2005–2016
   PubMed Web of Science ®Google Scholar
• Falkenberg J. H. F., Goselink H. M., Van der Harst D., Faber L., Fibbe W. E., Willemze R., Brand A., Goulmy E. Specific lysis of clonogenic leukemic cells (CLC) by cytotoxic T lymphocytes (CTL) against minor histocompatibility (MH) antigens: An in vitro model for graft vs leukemia (GVL). Exp. Hematol. 1990; 18: 682, (abstract)
   Google Scholar
• Jiang Y. Z., Kanfer E., Macdonald D., Cullis J. O., Goldman J. M., Barrett A. J. Graft-versus-leukaemia effect following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant. 1991; 8: 253–258
   PubMed Web of Science ®Google Scholar
• Vinci G., Vernant J. P., Nakazawa M., Zohair M., Katz A., Henri A., Rochant H., Breton-Gorius J., Vainchenker W. In vitro inhibition of normal human hematopoiesis by marrow CD3+, CD8+, HLA-DR+, HNK1 + lymphocytes. Blood 1988; 72: 1616–1621
   PubMed Web of Science ®Google Scholar
• Vinci G., Vernant J. P., Cordonnier C, Henri A., BretonGorius J., Rochant H., Vainchenker W. In vitro inhibition of hematopoiesis by HNK1, DR-positive T cells and monocytes after allogeneic bone marrow transplantation. Exp. Hematol. 1987; 15: 54–64
   PubMed Web of Science ®Google Scholar
• Lotze M. T., Grimm E. A., Mazumder A., Strausser J. L., Rosenberg S. A. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981; 41: 4420–4425
   PubMed Web of Science ®Google Scholar
• Lotzova E., Savary C. A., Herberman R. B. Induction of NK cell activity against fresh human leukemia in culture with the interleukin 2. J. Immunol. 1987; 138: 2718–2727
   PubMed Web of Science ®Google Scholar
• Dawson M. M., Johnston D., Taylor G. M., Moore M. Lymphokine activated killing of fresh human leukaemias. Leuk. Res. 1986; 10: 683–688
   PubMed Web of Science ®Google Scholar
• Oshimi K., Oshimi Y., Akutsu M., Takei Y., Saito H., Okada M., Mizoguchi H. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986; 68: 938–948
   PubMed Web of Science ®Google Scholar
• Fierro M. T., Liao X., Lusso P., Bonferroni M., Matera L., Cesano A., Lista P., Arione R., Forni G., Foa R. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 1988; 2: 50–54
   PubMed Web of Science ®Google Scholar
• Adler A., Chervenick P. A., Whiteside T. L., Lotzova E., Herberman R. B. Interleukin 2 induction of Iymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 1988; 71: 709–716
   PubMed Web of Science ®Google Scholar
• Trentin L., Pizzolo G., Feruglio C, Zambello R., Masciarelli M., Bulian P., Agostini C, Vinante F., Zanotti R., Semenzato G. Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. Cancer 1989; 64: 667–672
   PubMed Web of Science ®Google Scholar
• Archimbaud E., Bailly M., Doré J. F. Induci-bility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance. Br. J. Haematol. 1991; 77: 328–334
   PubMed Web of Science ®Google Scholar
• Hercend T., Takvorian T., Nowill A., Tantravahi R., Moingeon P., Anderson K. C, Murray C, Bohuon C, Ythier A., Ritz J. Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood 1986; 67: 722–728
   PubMed Web of Science ®Google Scholar
• Reittie J. E., Gottlieb D., Heslop H. E., Leger O., Drexler H. G., Hazelhurst G., Hoffbrand A. V., Prentice H. G., Brenner M. K. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351–1358
   PubMed Web of Science ®Google Scholar
• Nasarallah A. G., Miale T. D. Decreased natural killer cell activity in children with untreated acute leukemia. Cancer Res. 1983; 43: 5580–5585
   PubMed Web of Science ®Google Scholar
• Sorskaar D., Forre O., Albrechtsen D., Stavem P. Decreased natural killer cell activity versus normal natural killer cell markers in mononuclear cells from patients with smouldering leukemia. Scand. J. Haematol. 1986; 37: 154–161
   Google Scholar
• Guillou P. J., Sedman P. C., Ramsden C. W. Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro. Cancer Immunol., Immunother. 1989; 28: 43–53
   PubMed Web of Science ®Google Scholar
• Simonsson B., Nilsson B. 1., Rowe J. M. Treatment of minimal residual disease in acute leukemia—focus on immunotherapeutic options. Leukemia 1992; 6(Suppl 4)124–134
   PubMedGoogle Scholar
• Pizzolo G., Trentin L., Vinante F., Agostini C, Zambello R., Masciarelli M., Feruglio C., Dazzi F., Todeschini G., Chilosi M., et al. Natural killer cell function and lymphoid subpopulations in acute non-Iymphoblastic leukaemia in complete remission. Br. J. Cancer 1988; 58: 368–372
   PubMed Web of Science ®Google Scholar
• Melzer M. S., Nacy C. A. Delayed type hyper-sensitivity in the induction of activated, cytotoxic macrophages. Fundamental Immunology, P. Wee. Raven Press, New York 1989; 735–764
   Google Scholar
• Nathan C. F., Conn Z. A. Cellular components of inflammation: Monocytes and macrophages. Textbook of Rheumatology, W. N. Kelly, E. D. Harris, Jr, S. Ruddy, C. B. Sledge. W. B. Saunders Company, Philadelphia 1985; 144–169
   Google Scholar
• Fidler I. J., Schroit A. J. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim. Biophys. Acta 1988; 948: 151–173
   PubMed Web of Science ®Google Scholar
• Drysdale B. E., Agarwal S., Shin H. S. Macrophage-mediated tumoricidal activity: mechanisms of activation and cytotoxicity. Prog. Allergy 1988; 40: 111–161
   PubMedGoogle Scholar
• Hamilton T. A., Adams D. O. Mechanisms of macrophage-mediated tumor injury. Tumor Immunology: Mechanisms, Diagnosis, Therapy, J. Den, W. Oetter, E. J. Ruitenberg. Elsevier, Amsterdam 1987; 89–107
   Google Scholar
• Wunderlich J. R., Hodes R. J. Principles of tumor immunity: Biology of cellular immune responses. Biologic Therapy of Cancer, V. T. DeVita, S. Hellman, S. A. Rosenberg. J. B. Lippincott Co., Philadelphia 1991; 3–21
   Google Scholar
• Storb R., Deeg H. J., Whitehead J., Appelbaum F., Beatty P., Bensinger W., Buckner C. D., Clift R., Doney K., Farewell V., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis for acute graft versus host disease after marrow transplantation for leukemia. N. Eng. J. Med. 1986; 314: 729–735
   Google Scholar
• Santos G. E., Saral R., Burns W. H., Braine H. G., Sensenbrenner L. L., Wingard J. R., Yeager A M., Jones R., Ambinder R. F., Rowley S. D., et al. Allogeneic, syngeneic and autologous bone marrow transplantation in the acute leukemias—Baltimore experiences. Acta Haematol. 1987; 1: 175–180
   Google Scholar
• Foreman S. J., O'Donnell M. R., Nademanee A. P., Snyder D. S., Bierman P. J., Schmidt G. M., Fahey J. L., Stein A. S., Parker P. M., Blume K. Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1987; 70: 587–588
   PubMed Web of Science ®Google Scholar
• Jenkins M. K., Schwartz R. H., Pardoll D. M. Effects of cyclosporine A on T cell development and clonal deletion. Science 1988; 241: 1655–1658
   PubMed Web of Science ®Google Scholar
• Jones R. J., Vogelsang G. B., Hess A. D., Fanner E. R., Mann R. B., Geller R. B., Piantadosi S., Santos G. W. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 1: 754–757
   PubMed Web of Science ®Google Scholar
• Talbot D. C., Powles R. L., Sloane j. P., Rose J., Treleaven J., Aboud H., Helenglass G., Parikh P., Smith C., Rowley M., et al. Cyclosporine-induced graft-versushost disease following autologous bone marrow transplantation in acute myeloid leukemia. Bone Marrow Transplant. 1990; 6: 17–20
   PubMed Web of Science ®Google Scholar
• Yeager A. M., Vogelsang G. B., Jones R. J., Farmer E. R., Altamonte V., Hess A. D., Santos G. W. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031–3035
   PubMed Web of Science ®Google Scholar
• Lotze M. T. Interleukin-2: Basic principles. Biologic Therapy of Cancer, V. T. Devita, S. Hellman, S. A. Rosenberg. J. B. Lippincott Co., Philadelphia 1991; 123–141
   Google Scholar
• Lotze M. T., Matory Y. L., Ettinghausen S. E., Rayner A. A., Sharrow S. O., Seipp C. A., Custer M. D., Rsenberg S. A. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 1985; 135: 2865–2875
   PubMed Web of Science ®Google Scholar
• Reem G. H., Yeh N. H. Interleukin 2 regulates expression of its receptor and synthesis of gamma interferon by human T lymphocytes. Science 1984; 225: 429–430
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol. Today 1988; 9: 58–62
   PubMedGoogle Scholar
• Heslop H. E., Gottleib D. J., Bianchi A. C., Meager A., Prentice H. G., Mehta A. B., Hoffbrand A. V., Brenner M. K. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transfusion. Blood 1989; 74: 1374–1380
   PubMed Web of Science ®Google Scholar
• Blaise D., Olive D., Stoppa A. M., Viens P., Pourreau C., Lopez M., Attal M., Jasmin C., Monges G., Mawas C., et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092–1097
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Eng. J. Med. 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• Pacciucci P. A., Mandeli J., Oleksowicz L., Ameglio F., Holland J. F. Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion. Am. J. Med. 1990; 89: 308–312
   PubMed Web of Science ®Google Scholar
• Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J. Immunol. 1990; 144: 4472–4476
   PubMed Web of Science ®Google Scholar
• Larsson E. L., Joki A., Stalhandske T. Mechanism of action of the immunomodulator LS2616 on T cell responses. Int. J. lmmunopharmacol. 1987; 9: 425–431
   PubMed Web of Science ®Google Scholar
• Stalhandske T., Kalland T. Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat. Immunopharmacology 1986; 11: 87–92
   PubMed Web of Science ®Google Scholar
• Kalland T. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res. 1986; 46: 3018–3022
   PubMed Web of Science ®Google Scholar
• Kalland T., Alm G., Stalhandske T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J. Immunol. 1985; 134: 3956–3961
   PubMed Web of Science ®Google Scholar
• Kalland T., Maksimova A., Stalhandske T. Prophylaxis and treatment of experimental tumors with the immunomodulator LS 2616. Int. J. lmmunopharmacol. 1985; 7: 390
   Web of Science ®Google Scholar
• Stalhandske T., Jansson A. H., Karlstrom R., Maksimova A., Wigow U., Kalland T. Restoration of suppressed immune response with a new modulator quinoline-3-carboxamide (LS 2616) during experimental trypansoma infection. Int. J. lmmunopharmacol. 1985; 7: 391
   Web of Science ®Google Scholar
• Ilback N. G., Fohlman J., Slorach S., Friman G. Effects of the immunomodulator LS 2616 on lymphocyte sub-populations in murine Coxsackievirus B3 myocarditis. J. Immunol. 1989; 142: 3225–3228
   PubMed Web of Science ®Google Scholar
• Bengtsson M., Simonsson B., Carlsson K., Nilsson B., Smedmyr B., Termander B., Oberg G., Totterman T. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation 1992; 53: 882–888
   PubMed Web of Science ®Google Scholar
• Nilsson B. I., Bengtsson M., Simonsson B., Öberg G., Smedmyr B., Carlsson K., Rowe J. M., Totterman T. H. Immunotherapy of AML after ABMT—Scientific rationale and early experiences with Linomide. 1993, in press
   Google Scholar
• Tarkowski A., Gunnarsson K., Stalhandske T. Effects of LS-2616 administration upon the autoimmune disease of (NZB NZW) F1 hybrid mice. Immunology 1986; 59: 689–694
   Google Scholar
• Apperley J. F., Jones L., Hale G., Waldmann H., Hows J., Rombos Y., Tsatalas C., Marcus R. E., Goolden A. W., Gordon-Smith E. C., et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1986; 1: 53–66
   PubMed Web of Science ®Google Scholar
• Kolb H. J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465
   PubMed Web of Science ®Google Scholar
• Cullis J. O., Jiang Y. Z., Schwarer A. P., Hughes T. P., Barrett A. J., Goldman J. M. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379–1381
   PubMed Web of Science ®Google Scholar
• Cregan E. T. Biological response modifiers. Current Hematol. Oncol. 1988; 6: 27–58
   Google Scholar
• Koscielniak E., Bruchelt G., Treuner J., Uchanska-Zieg-ler B., Dopfer R., Vallbracht A., Neithammer D. Kinetics of restoration of interferon production after bone marrow transplantation in man. Bone Marrow Transplant. 1987; 1: 379–387
   PubMed Web of Science ®Google Scholar
• Reyes V. E., Klimpel G. R. Interferon alpha/ beta synthesis during acute graft-versus-host disease. Transplantation 1987; 43: 412–416
   PubMed Web of Science ®Google Scholar
• Cleveland M. G., Lane R. G., Klimpel G. R. Enhanced interferon-alpha/beta (IFN-alpha/beta) and defective IFN-gamma production in chronic graft versus host disease: a potential mechanism for immunosuppression. Cell. Immunol. 1987; 110: 120–130
   PubMed Web of Science ®Google Scholar
• Kleinerman E. S., Kurzrock R., Wyatt D., Quesada J. R., Gutterman J. U., Fidler I. J. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res. 1986; 46: 5401–5405
   PubMed Web of Science ®Google Scholar
• Le J., Prensky W., Yip Y. K., Chang Z., Hoffman T., Stevenson H. C., Balazs I., Sadlik J. R., Vilcek J. Activation of human monocyte cytotoxicity by natural and recombinant immune interferon. J. Immunol. 1983; 131: 2821–2826
   PubMed Web of Science ®Google Scholar
• Gidlund M., Orn A., Wigzell H., Senik A., Gresser 1. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 1987; 273: 759–763
   Web of Science ®Google Scholar
• Teichmann J. V., Sieber G., Ludwig W. D., Ruehl H. Immunosuppressive effects of recombinant interferonalpha during long-term treatment of cancer patients. Cancer 1989; 63: 1990–1993
   PubMed Web of Science ®Google Scholar
• Welsh R. M., Yang H., Bukowski J. F. The role of interferon in the regulation of virus infection by cytotoxic lymphocytes. Bioessays 1988; 8: 10–13
   PubMed Web of Science ®Google Scholar
• Zarling J. M., Sosman J., Eskra L., Borden E. C., Horoszewicz J. S., Carter W. A. Enhancement of T cell cytotoxic responses by purified human fibroblast interferon. J. Immunol. 1978; 121: 2002–2004
   PubMed Web of Science ®Google Scholar
• Alimena G., Morra E., Lazzarino M., Liberati A. M., Montefusco E., Inverardi D., Bernasconi P., Mancini M., Donti E., Grignani F. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988; 72: 642–647
   PubMed Web of Science ®Google Scholar
• Meyers J. D., Flournoy N., Sanders J. E., McGuffin R. W., Newton B. A., Fisher L. D., Lum L. G., Appelbaum F. R., Doney K., Sullivan K. M., et al. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann. Int. Med. 1987; 107: 809–816
   PubMed Web of Science ®Google Scholar
• Klingemann H. G., Grigg A. P., Wilkie-Boyd K., Barnett M. J., Eaves A. C., Reece D. E., Shepherd J. D., Phillips G. L. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood 1992; 79: 3397
   PubMedGoogle Scholar